Merck (NYSE: MRK) announced results from a pre-specified exploratory analysis of the investigational IMPROVE-IT study of more than 18,000 patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE